146 related articles for article (PubMed ID: 23435531)
1. In vitro and in vivo responses to high and low doses of nitrogen-containing bisphosphonates suggest engagement of different mechanisms for inhibition of osteoclastic bone resorption.
Fisher JE; Rosenberg E; Santora AC; Reszka AA
Calcif Tissue Int; 2013 Jun; 92(6):531-8. PubMed ID: 23435531
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
4. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
5. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
6. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Fisher JE; Rodan GA; Reszka AA
Endocrinology; 2000 Dec; 141(12):4793-6. PubMed ID: 11108295
[TBL] [Abstract][Full Text] [Related]
8. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
[TBL] [Abstract][Full Text] [Related]
10. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
13. Human osteoclast formation and activity in vitro: effects of alendronate.
Breuil V; Cosman F; Stein L; Horbert W; Nieves J; Shen V; Lindsay R; Dempster DW
J Bone Miner Res; 1998 Nov; 13(11):1721-9. PubMed ID: 9797481
[TBL] [Abstract][Full Text] [Related]
14. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
15. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
[TBL] [Abstract][Full Text] [Related]
16. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy.
Murakami H; Nakamura T; Tsurukami H; Abe M; Barbier A; Suzuki K
J Bone Miner Res; 1994 Sep; 9(9):1355-64. PubMed ID: 7529459
[TBL] [Abstract][Full Text] [Related]
17. Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate.
Tanaka T; Saito M; Chazono M; Kumagae Y; Kikuchi T; Kitasato S; Marumo K
J Biomed Mater Res A; 2010 May; 93(2):469-74. PubMed ID: 19582838
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Curr Rheumatol Rep; 2003 Feb; 5(1):65-74. PubMed ID: 12590887
[TBL] [Abstract][Full Text] [Related]
19. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Thompson K; Dunford JE; Ebetino FH; Rogers MJ
Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
[TBL] [Abstract][Full Text] [Related]
20. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
